SecBot SecBot

BOLT

Bolt Biotherapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001641281 Biotech & Drug Discovery
$6.37 −0.22 (−3.34%)
Oct 27 4:00 PM ET · prev $6.59
Market cap
$12.1M
Nano cap
Median target
$41.00
+544% · range $7.00–75.00
Next earnings
Nov 10
in 14 days
1 year
+11.4%
from $5.72 · Oct 28
30 days
+84.1%
from $3.46
52-week range
$3.18–7.09
−10% from high · low Aug 18
Avg volume 20D
694.3K
Oct 23 spike 12.88M
Short interest
15.8K
≈0.8% of shares · −38.8%
Days to cover
1.0
at average volume
Insider net
−$122.7K
2 buyers · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 10, 2026
Strongest MIXED Bolt Biotherapeutics (BOLT) has entered into a definitive merger agreement to acquire Prana Therapies in a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders bought $5.6K at an average $4.01. 3 insiders sold $128.3K. Price is 59% above their cost.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −38.8% to 15.8K shares. 1.0 days to cover, ≈0.8% of shares.

  • TrendUPTREND

    62% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD98,625$379.7K
CITADEL ADVISORS LLCDOUBLED56,903$219.1K
GEODE CAPITAL MANAGEMENT, LLCTRIM19,119$73.6K
UBS Group AGTRIM255$982.00
RENAISSANCE TECHNOLOGIES LLCADD77,225$312.0K
GEODE CAPITAL MANAGEMENT, LLCADD28,791$116.3K
UBS Group AGADD787$3.2K
RENAISSANCE TECHNOLOGIES LLCADD55,025$300.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 2 analysts

Price is below the lowest target. Median implies +544%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 29, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
May 28, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$5.6K
bought · 2 insiders
$128.3K
sold · 3 insiders
+59.0%
vs their $4.01 cost
DateInsiderTypeValue
Oct 23, 2026🔒 Fresh data, subscribers onlyOTHER
Oct 23, 2026🔒 Fresh data, subscribers onlyOTHER
Oct 23, 2026🔒 Fresh data, subscribers onlyAWARD
Oct 23, 2026🔒 Fresh data, subscribers onlyAWARD
Sep 18, 2026
Quinn William P.
President, CEO and CFO
SELL$29.6K
Sep 18, 2026
Nemec Sarah
Senior VP, Finance and PAO
SELL$13.2K
Sep 18, 2026
Yonehiro Grant
Chief Operating Officer
SELL$22.2K
Sep 17, 2026
Quinn William P.
President, CEO and CFO
SELL$21.7K

Earnings setup

Estimates
Nov 10
reports in 14 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
15,751
shares short
-38.8%
vs prior settlement
1.0
days to cover
≈0.8%
of shares outstanding
Trading halts
Oct 23, 2026Volatility PauseResumed
Oct 23, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 23, 2026 SEC
Bolt Biotherapeutics (BOLT) has entered into a definitive merger agreement to acquire Prana Therapies in a…
8-K — Impact 7/10
Oct 23, 2026 Trading halt
Halt Resumed: BOLT — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-23T13:57:09.000Z | Resumed 2026-10-23T14:02:09.000Z
Oct 23, 2026 Insider
🔒 Fresh data, subscribers only
Oct 23, 2026 Insider
🔒 Fresh data, subscribers only
Oct 23, 2026 Insider
🔒 Fresh data, subscribers only
Oct 6, 2026 SEC
Bolt Biotherapeutics amended its lease to accelerate the expiration date to December 31, 2027 (or earlier upon a…
8-K — Impact 6/10
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
98,625 shares ($379.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
BOLT Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Oct 23, 2026
Trading halt
Halt Resumed: BOLT — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-23T13:57:09.000Z | Resumed 2026-10-23T14:02:09.000Z
Oct 23, 2026
Trading halt
Trading Halt: BOLT — LUDP (Volatility Trading Pause)
Bolt Biotherapeutics, Inc. | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Oct 23, 2026
Trading halt
Halt Resumed: BOLT — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T12:40:00.000Z | Resumed 2026-10-23T13:50:00.000Z
Oct 23, 2026
Trading halt
Trading Halt: BOLT — T3 (News and Resumption Times)
Bolt Biotherapeutics, Inc. | Market: NASDAQ | Code: T3 — News and Resumption Times
Oct 23, 2026
Trading halt
Trading Halt: BOLT — T1 (News Pending)
Bolt Biotherapeutics, Inc. | Market: NASDAQ | Code: T1 — News Pending

SecBot reports

5 filings · 1 press release · 0 bullish · 2 bearish · 1 mixed · 2 neutral
All BOLT filing & press-release reports (6)